2025 brings revolutionary hair loss treatments: UCLA’s PP405 molecule shows 31% hair density increase in trials, while ET-02 outperforms minoxidil 6x faster. Discover the latest breakthroughs, clinical trials, and FDA-approved therapies transforming hair restoration.
Upadacitinib (RINVOQ®) achieved major Phase 3 success in non-segmental vitiligo, meeting key repigmentation endpoints at Week 48. Clinical data show significant total and facial VASI improvement, consistent safety, and promise for patients seeking systemic repigmentation therapy. MI Skin Clinic reviews the evidence behind this new era of JAK1-targeted dermatology.
Expert dermatology care available for you
Your information is secure and private
